Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.
Publication
, Journal Article
McGrail, DJ; Pilié, PG; Rashid, NU; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, AB; Ueno, NT; Ferrarotto, R; Lin, S-Y ...
Published in: Ann Oncol
September 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
September 2021
Volume
32
Issue
9
Start / End Page
1194 / 1197
Location
England
Related Subject Headings
- Prevalence
- Oncology & Carcinogenesis
- Neoplasms
- Humans
- Antibodies, Monoclonal, Humanized
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., … Lin, S.-Y. (2021). Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Ann Oncol, 32(9), 1194–1197. https://doi.org/10.1016/j.annonc.2021.06.017
McGrail, D. J., P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, et al. “Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.” Ann Oncol 32, no. 9 (September 2021): 1194–97. https://doi.org/10.1016/j.annonc.2021.06.017.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, et al. Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Ann Oncol. 2021 Sep;32(9):1194–7.
McGrail, D. J., et al. “Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.” Ann Oncol, vol. 32, no. 9, Sept. 2021, pp. 1194–97. Pubmed, doi:10.1016/j.annonc.2021.06.017.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin S-Y. Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Ann Oncol. 2021 Sep;32(9):1194–1197.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
September 2021
Volume
32
Issue
9
Start / End Page
1194 / 1197
Location
England
Related Subject Headings
- Prevalence
- Oncology & Carcinogenesis
- Neoplasms
- Humans
- Antibodies, Monoclonal, Humanized
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis